Document Detail


Fluid resuscitation of hemorrhagic shock with hemoglobin vesicles in beagle dogs: pilot study.
MedLine Citation:
PMID:  22288842     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Abstract: Resuscitation of hemorrhagic shock requires volume replacement and restoration of oxygen metabolism. Artificial oxygen carriers that can both expand blood volume and deliver oxygen have been developed as resuscitation fluids. We employed hemoglobin vesicles (HbV), a cellular-type artificial oxygen carrier, in a Beagle dog hemorrhagic shock model to prove the efficacy of HbV. Hemorrhagic shock was introduced in splenectomized Beagle dogs by withdrawing 50% of circulating blood from the femoral artery. Shock was maintained for 60 minutes before isovolemic resuscitation with HbV dispersed in 5% albumin in saline (HbV), lactated Ringer's solution (LR), 5% human serum albumin in saline (HSA), or autologous shed blood (ASB). One animal in the LR group died 150 min after resuscitation. All other animals survived 4 h of the experiment. The mean arterial pressure remained significantly lower in the LR group than in the HbV group but did not differ significantly among the HbV, Alb, and ASB groups. Immediately after resuscitation, the HbV group showed a significantly higher mean pulmonary arterial pressure, which decreased within 10 minutes to the baseline level. The cardiac output was significantly higher in the Alb group than in the others, indicating compensation for low oxygen delivery per unit blood. The post-resuscitation hematocrit was 36% in the ASB group and decreased in the other groups (20-22%). Serum chemistry data from the HbV group were unremarkable. HbV contributed 32% of the post-resuscitation oxygen delivery. Collectively, HbV is comparable to ASB and HSA as a resuscitation fluid and is an effective oxygen carrier.
Authors:
Manabu Yamamoto; Hirohisa Horinouchi; Koichi Kobayashi; Yasuhisa Seishi; Natsue Sato; Manabu Itoh; Hiromi Sakai
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Artificial cells, blood substitutes, and immobilization biotechnology     Volume:  40     ISSN:  1532-4184     ISO Abbreviation:  Artif Cells Blood Substit Immobil Biotechnol     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-01-31     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9431307     Medline TA:  Artif Cells Blood Substit Immobil Biotechnol     Country:  England    
Other Details:
Languages:  eng     Pagination:  179-95     Citation Subset:  IM    
Affiliation:
Department of Surgery, School of Medicine, Keio University , Tokyo , Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Microencapsulated Saccharomyces cerevisiae Column Bioreactor for Potential Use in Renal Failure Urem...
Next Document:  Enantioselective analysis of triazole fungicide myclobutanil in cucumber and soil under different ap...